For the last 21/2 months currently treated for thrush; Third dose:15Sep2021  and Expiry date: 31Aug2021; After receiving all three doses he has had COPD flare ups after each dose; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 66 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administration date 15Sep2021 (Lot number: EW0168, Expiration Date: 31Aug2021) at the age of 66 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "COPD", start date: 2007 (ongoing); "Cornary artery disease", start date: 2014 (ongoing), notes: open heat surgery cardiac tamponade stent(1st); "Coronary artery disease", start date: 2018 (unspecified if ongoing), notes: 2018- stent in RCA(2nd); "COPD Emphysema", start date: 2007 (ongoing). Family history included: "Heart disease" (unspecified if ongoing), notes: family medical history; "Diabetes" (unspecified if ongoing), notes: family medical history. Concomitant medication(s) included: PREDNISONE taken for chronic obstructive pulmonary disease (ongoing); MEROPENEM taken for chronic obstructive pulmonary disease; NYSTATIN taken for chronic obstructive pulmonary disease; LIDOCAINE taken for chronic obstructive pulmonary disease. Vaccination history included: Bnt162b2 (1s Dose, Route of administration: intramuscular, Batch /Lot number: EL9269, Exp: 31May2021), administration date: 17Feb2021, for COVID-19 Immunization, reaction(s): "After receiving all three doses he has had COPD flare ups after each dose", "After receiving all three doses he has had COPD flare ups after each dose"; Bnt162b2 (2nd Dose, Route of administration: intramuscular, Batch /Lot number: EN6203, Exp: 30Jun2021), administration date: 10Mar2021, for Covid-19 immunization, reaction(s): "After receiving all three doses he has had COPD flare ups after each dose", "After receiving all three doses he has had COPD flare ups after each dose". The following information was reported: CONDITION AGGRAVATED (non-serious) with onset 2021, outcome "not recovered", described as "After receiving all three doses he has had COPD flare ups after each dose"; EXPIRED PRODUCT ADMINISTERED (non-serious) with onset 15Sep2021, outcome "unknown", described as "Third dose:15Sep2021 and Expiry date: 31Aug2021"; CANDIDA INFECTION (non-serious), outcome "unknown", described as "For the last 21/2 months currently treated for thrush". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of condition aggravated.  Additional information: Patient stated that he receives two doses of Pfizer covid vaccine and booster dose. After receiving all three doses he has had COPD flare ups after each dose. He reports flare up lasted 6 months and is seeking Pfizer recommendation regarding treatment. He stated he will not be able to take prednisone for 6 months, it will kill him. It was also reported that patient having some kind of reaction to Pfizer Covid-19 Vaccine where it is triggering his COPD to flare up. He has COPD and it is triggering his COPD to flare up. He got the first two shots of Pfizer Covid-19 Vaccine in February and March and he couldn't get control of his COPD for 6 months. He went and got the booster shot of Pfizer Covid-19 Vaccine a couple of weeks ago and it flared his COPD up again. He can't take Prednisone for another 6 weeks. He asked for information regarding this event relative to the Pfizer Covid-19 Vaccine, recommendations. The patient did not have prior vaccination within 4 weeks. The patient received Meropenem administered IV -42 infusions the 1st -2 weeks of November, Nystatin and lidocaine for the treatment of COPD flare-up.  No follow-up attempts are possible. No further information is expected.